AUG 7·SEC EDGARLow
Kaplan Johanne purchased $30K of PMN
Kaplan Johanne (Chief Development Officer) purchased 2,280 shares of ProMIS Neurosciences Inc. (PMN) at $13.30 on 2026-08-05.
StockNASDAQ · US · USDHealthcare · Biotechnology
$PMN
ProMIS Neurosciences Inc.
Price · $PMNvia TradingView
AI sentiment · 7d1 articles
- Bullish
- 0
- Neutral
- 1
- Bearish
- 0
Top stories · $PMNMore →
AUG 3·thestarphoenix.com
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
ProMIS Neurosciences Inc. (Nasdaq: PMN) said it will release its second-quarter 2026 financial results for the period ended June 30, 2026 and provide a business update on Aug. 13, 2026. The company will hold an investor conference call and webcast at 4:30 p.m. ET, with a replay available afterward on its website.
JUL 29·rttnews.com
Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
PMN sentiment & insider activity
Over the past 7 days, alphai's AI scored 1 news story mentioning PMN (ProMIS Neurosciences Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent PMN coverage spans technology, earnings and market movers.
In the last 30 days, PMN insiders filed 1 SEC Form 4 transaction — 1 purchase ($30K) and no sales. The most active reporter was Kaplan Johanne, Chief Development Officer, with 1 filing.
What's driving PMN
A small open-market insider purchase is a mild positive signal, but it is not a fundamental catalyst and lacks 10b5-1 context.
This is a scheduled earnings and corporate-update event, setting a near-term catalyst window for PMN’s stock and options.
Interim safety and biomarker positivity reduces downside risk and can re-rate the program ahead of 12-month topline.
No ARIA-E reduces a key safety overhang for anti-amyloid therapies, while biomarker declines suggest early target engagement but remain blinded.
Early safety and biomarker movement for PMN310 reduce near-term ARIA risk concerns, but clinical efficacy remains unblinded later in 2027.
alphai scores every news story that mentions PMN with an AI model for sentiment and relevance, and aggregates insider trades from ProMIS Neurosciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $PMN
Score
Kaplan Johanne purchased $30K of PMN
Kaplan Johanne (Chief Development Officer) purchased 2,280 shares of ProMIS Neurosciences Inc. (PMN) at $13.30 on 2026-08-05.
1 min readProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026
ProMIS Neurosciences Inc. (Nasdaq: PMN) said it will release its second-quarter 2026 financial results for the period ended June 30, 2026 and provide a business update on Aug. 13, 2026. The company will hold an investor conference call and webcast at 4:30 p.m. ET, with a replay available afterward on its website.
1 min read
Top Biotech Gainers: KNSA Soars On Q2 Results, TRIB, OPK On Watch, MPLT On The Mend?
Biotech gainers included Trinity Biotech (TRIB), which rose 36% after Q2 results and a one-for-thirty reverse ADS split to regain Nasdaq bid compliance. OPKO Health (OPK) gained 33% on Q2 revenue of $163.5M and softer Q3/full-year guidance. Kiniksa (KNSA) jumped 25% after raising 2026 net product revenue outlook to $980M-$995M. MapLight (MPLT) rebounded 24% after mixed Phase 2 schizophrenia data. ProMIS (PMN) rose 24% on interim Alzheimer’s data; Prelude (PRLD) rose 19% without specific news.
7 min readPromis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data
Promis Neurosciences (NASDAQ:PMN) reported interim Phase 1b safety data for PMN310 in Alzheimer’s. As of July 22, there were no ARIA-E cases in the blinded safety population and no treatment-related serious adverse events. Total ARIA was 4.4% (mild, asymptomatic ARIA-H). Biomarkers showed declines in plasma p-tau217 and CSF MTBR-tau243. Dosing runs to Dec 2026; unblinding expected early 2027.
5 min read
Small-Cap ProMIS Neurosciences Says Lead Drug Shows Encouraging Action in Early Alzheimer's Study - ProMI
ProMIS Neurosciences reported a blinded interim safety analysis of PMN310 in an early Alzheimer’s study with 136 patients. It said no ARIA-E cases occurred by the cutoff, total ARIA incidence was 4.4% and limited to mild, asymptomatic ARIA-H. No treatment-related serious adverse events or discontinuations were reported, including in APOE4 carriers. Unblinded 12-month topline results are expected in Q1 2027.
5 min readWhy is ProMIS Neurosciences stock surging today? By Investing.com
ProMIS Neurosciences (PMN) shares rose about 16% pre-open after the company reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310. In 136 patients, there were zero ARIA-E cases, 4.4% total ARIA incidence, and no treatment-related serious adverse events. Chardan started coverage with a Buy and $20 target.
4 min readAI concerns pressure chipmakers premarket; UPS, Carrier rise By Investing.com
U.S. stock futures were mixed as renewed concerns about AI spending weighed on semiconductor shares ahead of major tech earnings and the Fed. Chipmakers fell broadly after an Asian selloff and worries about AI infrastructure financing and China competition, plus a CXMT IPO. UPS and Carrier rose on Q2 results and raised guidance; Altimmune, ProMIS, BuzzFeed, and Cadence also gained.
4 min readProMIS Neurosciences stock jumps on trial safety data By Investing.com
ProMIS Neurosciences Inc. (NASDAQ:PMN) shares rose about 13% after it reported positive blinded six-month interim safety and biomarker data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s trial. In 136 patients, no ARIA-E was seen; total ARIA was 4.4% and mild. The company expects topline 12-month results in Q1 2027.
4 min readProMIS Neurosciences Inc.: ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer's Disease Trial
ProMIS Neurosciences (Nasdaq: PMN) reported blinded six-month interim safety and biomarker results from its PRECISE-AD Phase 1b trial of PMN310 in 136 Alzheimer’s patients. As of the cutoff, no ARIA-E occurred and total ARIA was 4.4% (mild, asymptomatic ARIA-H only). Early biomarker shifts in pTau217 and CSF MTBR-tau243 were reported. Unblinded 12-month topline data are expected in Q1 2027.
5 min readProMIS Reports First Human PMN310 Target Engagement In Alzheimer's Disease; Stock Up
ProMIS Neurosciences (PMN) reported first human target engagement for its Alzheimer’s candidate PMN310, showing dose-dependent reductions in toxic amyloid-beta oligomers in cerebrospinal fluid at 3 and 29 days after a single dose, with generally good tolerability and a ~27-day half-life. Data were presented at AAIC 2026; PMN310 is in Phase 1b PRECISE-AD, with interim data expected soon.
5 min read